Niacin (Synonyms: Nicotinic acid; Vitamin B3; ニコチン酸)

Name: Niacin
Brand: MedChemExpress
SKU: HY-B0143
Rating: 5.0 (12 reviews)

製品番号: HY-B0143 純度: 99.96%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Niacin (Vitamin B3) is an orally active water-soluble B3 vitamin that is an essential nutrient for humans. Niacin (Vitamin B3) plays a key role in energy metabolism, cell signaling cascades regulating gene expression and apoptosis. Niacin (Vitamin B3) is also used in the study of cardiovascular diseases.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 59-67-6

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 60	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 60	在庫あり	Estimated Time of Arrival: December 31
Solid
500 mg	$55	在庫あり	Estimated Time of Arrival: December 31
1 g	$66	在庫あり	Estimated Time of Arrival: December 31
5 g	$86	在庫あり	Estimated Time of Arrival: December 31
10 g	$127	在庫あり	Estimated Time of Arrival: December 31
25 g	$210	在庫あり	Estimated Time of Arrival: December 31
50 g		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 12 publication(s) in Google Scholar

Other Forms of Niacin:

Niacin-d₄ 在庫あり
Niacin-¹³C₆ 在庫あり
Niacin (standard) 在庫あり
Niacin-¹⁵N,¹³C₃ お問い合わせ
Niacin hydrochloride お問い合わせ

顧客検証

Histological Imaging/Staining

ELISA

In Vivo Efficacy Study

: Niacin purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Oct 18;26(20):10132. [Abstract]; Seven-week-old male C57BL/6 mice were shaved and treated topically with vehicle, 3% rebamipide, 0.5% niacin (NA, lipolysis inhibitor), 0.05% rosiglitazone (RSG, PPARγ agonist), or combination therapies for 26 days (n = 6 for each group). Photographs were taken on day 26 post-treatment. H&E staining of skin sections revealed hair follicle morphology. Ki67 immunofluorescent staining showed that rebamipide-induced hair regeneration was inhibited by NA and RSG.

: Niacin purchased from MedChemExpress. Usage Cited in: Commun Biol. 2023 Mar 2;6(1):235. [Abstract]; Niacin (400 mg/kg/day). Body weight of mice during the experiment after supplementation with the MCD diet decreased gradually.

: Niacin purchased from MedChemExpress. Usage Cited in: Mil Med Res. 2022 Aug 23;9(1):46. [Abstract]; BMDMs (LPS-primed) were treated with propionate (C3, 3 mmol/L), butyrate (C4, 0.5 mmol/L), TSA (50 nmol/L), Panobinostat (25 nmol/L), AR42062 (25 μmol/L), 4-CMTB (100 μmol/L), and niacin (1 mmol/L; 6 h) and then stimulated with CoCrMo alloy particles.

: Niacin purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2022 Mar 9;20(1):120. [Abstract]; BMDMs (LPS-primed) were treated with different doses of BHB, Niacin (100 μM; 6 h), TSA (50 nM), and LBH589 (25 nM) and stimulated with CoCrMo particles. Supernatants were collected for Caspase-1 and IL-1β detection by western blot.

: Niacin purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2022 Mar 9;20(1):120. [Abstract]; BMDMs (LPS-primed) were treated with different doses of BHB, Niacin (100 μM; 6 h), TSA (50 nM), and LBH589 (25 nM) and stimulated with CoCrMo particles. IL-1β was analyzed by ELISA in the supernatants.

: Niacin purchased from MedChemExpress. Usage Cited in: Glia. 2018 Feb;66(2):256-278. [Abstract]; Representative images and quantitative analysis showing the effects of Niacin (1 mM, 10 min) and MK-6892 (10 lM, 10 min) on Akt phosphorylation levels in primary cultured microglia.

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Human Endogenous Metabolite Microbial Metabolite

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	EC₅₀	0.73 3 Compound: Niacin	Activation of GPR109A in human A431 cells assessed as suppression of forskolin-induced cAMP production after 30 mins Activation of GPR109A in human A431 cells assessed as suppression of forskolin-induced cAMP production after 30 mins	[PMID: 26784936]
A-431	EC₅₀	0.73 3 Compound: Niacin	Activation of GPR109A in human A431 cells assessed as suppression of forskolin-induced cAMP production after 30 mins Activation of GPR109A in human A431 cells assessed as suppression of forskolin-induced cAMP production after 30 mins	[PMID: 26784936]
A-431	EC₅₀	0.73 3 Compound: Niacin	Activation of GPR109A in human A431 cells assessed as suppression of forskolin-induced cAMP production after 30 mins Activation of GPR109A in human A431 cells assessed as suppression of forskolin-induced cAMP production after 30 mins	[PMID: 26784936]
Adipocyte	EC₅₀	0.9 3 Compound: NA	Inhibition of isoproterenol-induced lipolysis in human subcutaneous adipocytes after 5 hrs Inhibition of isoproterenol-induced lipolysis in human subcutaneous adipocytes after 5 hrs	[PMID: 17452318]
Adipocyte	EC₅₀	0.9 3 Compound: NA	Inhibition of isoproterenol-induced lipolysis in human subcutaneous adipocytes after 5 hrs Inhibition of isoproterenol-induced lipolysis in human subcutaneous adipocytes after 5 hrs	[PMID: 17452318]
Adipocyte	IC₅₀	0.07 3 Compound: Niacin	Inhibition of lipolysis in IBMX-stimulated human adipocytes assessed as glycerol release after 5 hrs Inhibition of lipolysis in IBMX-stimulated human adipocytes assessed as glycerol release after 5 hrs	[PMID: 19309152]
Adipocyte	IC₅₀	0.06 3 Compound: Niacin	Antidyslipidemic activity in human adipocytes assessed as inhibition of isoproteranol-induced production of free fatty acids Antidyslipidemic activity in human adipocytes assessed as inhibition of isoproteranol-induced production of free fatty acids	[PMID: 20363624]
Adipocyte	IC₅₀	0.06 3 Compound: Niacin	Antidyslipidemic activity in human adipocytes assessed as inhibition of isoproteranol-induced production of free fatty acids Antidyslipidemic activity in human adipocytes assessed as inhibition of isoproteranol-induced production of free fatty acids	[PMID: 20363624]
Adipocyte	EC₅₀	0.9 3 Compound: NA	Inhibition of isoproterenol-induced lipolysis in human subcutaneous adipocytes after 5 hrs Inhibition of isoproterenol-induced lipolysis in human subcutaneous adipocytes after 5 hrs	[PMID: 17452318]
Adipocyte	IC₅₀	0.07 3 Compound: Niacin	Inhibition of lipolysis in IBMX-stimulated human adipocytes assessed as glycerol release after 5 hrs Inhibition of lipolysis in IBMX-stimulated human adipocytes assessed as glycerol release after 5 hrs	[PMID: 19309152]
Adipocyte	IC₅₀	0.08 3 Compound: Niacin	Inhibition of lipolysis in human adipocytes assessed as free glycerol level Inhibition of lipolysis in human adipocytes assessed as free glycerol level	[PMID: 20452209]
CCRF-CEM	IC₅₀	> 500 3 Compound: Niacin	Cytotoxicity against human CEM cells assessed as growth inhibition after 72 hrs by coulter counter method Cytotoxicity against human CEM cells assessed as growth inhibition after 72 hrs by coulter counter method	[PMID: 28238612]
CHO	EC₅₀	0.027 3 Compound: Niacin	Agonist activity at GPR109a expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP production by HTRF assay Agonist activity at GPR109a expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP production by HTRF assay	[PMID: 20363624]
Adipocyte	IC₅₀	0.08 3 Compound: Niacin	Inhibition of lipolysis in human adipocytes assessed as free glycerol level Inhibition of lipolysis in human adipocytes assessed as free glycerol level	[PMID: 20452209]
Adipocyte	IC₅₀	0.07 3 Compound: Niacin	Inhibition of lipolysis in IBMX-stimulated human adipocytes assessed as glycerol release after 5 hrs Inhibition of lipolysis in IBMX-stimulated human adipocytes assessed as glycerol release after 5 hrs	[PMID: 19309152]
CCRF-CEM	IC₅₀	> 500 3 Compound: Niacin	Cytotoxicity against human CEM cells assessed as growth inhibition after 72 hrs by coulter counter method Cytotoxicity against human CEM cells assessed as growth inhibition after 72 hrs by coulter counter method	[PMID: 28238612]
CCRF-CEM	IC₅₀	>500 3 Compound: Niacin	Cytotoxicity against human CEM cells assessed as growth inhibition after 72 hrs by coulter counter method Cytotoxicity against human CEM cells assessed as growth inhibition after 72 hrs by coulter counter method	[PMID: 28238612]
CHO	EC₅₀	1 3 Compound: nicotinic acid	Agonist activity at human GPR109A receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human GPR109A receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 18752940]
CHO	EC₅₀	0.12 3 Compound: niacin	Activity at GPR109a in CHO cells assessed as inhibition of forskolin-induced cAMP generation Activity at GPR109a in CHO cells assessed as inhibition of forskolin-induced cAMP generation	[PMID: 17358052]
CHO	IC₅₀	1 3 Compound: niacin	Agonist activity at human niacin receptor expressed in CHO cells by GTPgammaS binding assay Agonist activity at human niacin receptor expressed in CHO cells by GTPgammaS binding assay	[PMID: 18477506]
CHO	EC₅₀	51 1 Compound: niacin, Niaspan	Agonist activity at human GPR109a expressed in CHO cells assessed as decrease in forskolin-stimulated cAMP production by HTRF assay Agonist activity at human GPR109a expressed in CHO cells assessed as decrease in forskolin-stimulated cAMP production by HTRF assay	[PMID: 22435740]
CHO	EC₅₀	0.027 3 Compound: Niacin	Agonist activity at GPR109a expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP production by HTRF assay Agonist activity at GPR109a expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP production by HTRF assay	[PMID: 20363624]
CHO	EC₅₀	0.027 3 Compound: Niacin	Agonist activity at GPR109a expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP production by HTRF assay Agonist activity at GPR109a expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP production by HTRF assay	[PMID: 20363624]
CHO	EC₅₀	1 3 Compound: nicotinic acid	Agonist activity at human GPR109A receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human GPR109A receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 18752940]
CHO-K1	EC₅₀	1 3 Compound: Niacin	Agonist activity at human GPR109A expressed in CHOK1 cells by [35S]GTPgammaS binding assay Agonist activity at human GPR109A expressed in CHOK1 cells by [35S]GTPgammaS binding assay	[PMID: 19309152]
CHO	IC₅₀	1 3 Compound: niacin	Agonist activity at human niacin receptor expressed in CHO cells by GTPgammaS binding assay Agonist activity at human niacin receptor expressed in CHO cells by GTPgammaS binding assay	[PMID: 18477506]
CHO	EC₅₀	0.12 3 Compound: niacin	Activity at GPR109a in CHO cells assessed as inhibition of forskolin-induced cAMP generation Activity at GPR109a in CHO cells assessed as inhibition of forskolin-induced cAMP generation	[PMID: 17358052]
CHO-K1	EC₅₀	1 3 Compound: niacin	Agonist activity at human GPR109A expressed in CHOK1 cells by [35S]GTP-gamma-S binding assay Agonist activity at human GPR109A expressed in CHOK1 cells by [35S]GTP-gamma-S binding assay	[PMID: 17994679]
CHO	EC₅₀	1 3 Compound: nicotinic acid	Agonist activity at human GPR109A receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human GPR109A receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 18752940]
CHO	IC₅₀	0.14 3 Compound: Niacin	Displacement of [3H]niacin from human GPR109A expressed in CHO cells Displacement of [3H]niacin from human GPR109A expressed in CHO cells	[PMID: 19309152]
CHO-K1	EC₅₀	1.4 3 Compound: nicotinic acid	Agonist activity at human GPR109A receptor expressed in CHO-K1 cells by [35S]GTPgammaS guanine nucleotide exchange assay Agonist activity at human GPR109A receptor expressed in CHO-K1 cells by [35S]GTPgammaS guanine nucleotide exchange assay	[PMID: 18760600]
CHO	EC₅₀	100 1 Compound: Nicotinic acid	Agonist activity at human recombinant GPR109a expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation Agonist activity at human recombinant GPR109a expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation	[PMID: 24900295]
CHO	IC₅₀	0.14 3 Compound: niacin	Displacement of [3H]Niacin from human niacin receptor expressed in CHO cells Displacement of [3H]Niacin from human niacin receptor expressed in CHO cells	[PMID: 18477506]
CHO-K1	EC₅₀	47 1 Compound: Nicotinic acid	Agonist activity at HCA2 receptor (unknown origin) expressed in CHOK1 cells assessed as ERK1/2 phosphorylation by ELISA Agonist activity at HCA2 receptor (unknown origin) expressed in CHOK1 cells assessed as ERK1/2 phosphorylation by ELISA	[PMID: 25737085]
CHO	EC₅₀	51 1 Compound: niacin, Niaspan	Agonist activity at human GPR109a expressed in CHO cells assessed as decrease in forskolin-stimulated cAMP production by HTRF assay Agonist activity at human GPR109a expressed in CHO cells assessed as decrease in forskolin-stimulated cAMP production by HTRF assay	[PMID: 22435740]
CHO	IC₅₀	0.15 3 Compound: nicotinic acid	Displacement of [3H]nicotinic acid from human GPR109A receptor expressed in CHO cells Displacement of [3H]nicotinic acid from human GPR109A receptor expressed in CHO cells	[PMID: 18752940]
CHO-K1	EC₅₀	527 1 Compound: NA	Agonist activity at cloned human GPR109A receptor expressed in CHO-K1 cells by [35S]GTPgammaS binding assay Agonist activity at cloned human GPR109A receptor expressed in CHO-K1 cells by [35S]GTPgammaS binding assay	[PMID: 20184326]
CHO	EC₅₀	99 1 Compound: NA, niacin	Agonist activity at human recombinant GPR109a expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation Agonist activity at human recombinant GPR109a expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation	[PMID: 24900372]
CHO-K1	EC₅₀	1 3 Compound: Niacin	Agonist activity at human GPR109A expressed in CHOK1 cells by [35S]GTPgammaS binding assay Agonist activity at human GPR109A expressed in CHOK1 cells by [35S]GTPgammaS binding assay	[PMID: 19309152]
CHO-K1	EC₅₀	580 1 Compound: NA	Activation of GPR109A receptor in CHOK1 cells assessed as ERK1/2 MAP kinase activation by ELISA Activation of GPR109A receptor in CHOK1 cells assessed as ERK1/2 MAP kinase activation by ELISA	[PMID: 17452318]
CHO-K1	EC₅₀	1 3 Compound: niacin	Agonist activity at human GPR109A expressed in CHOK1 cells by [35S]GTP-gamma-S binding assay Agonist activity at human GPR109A expressed in CHOK1 cells by [35S]GTP-gamma-S binding assay	[PMID: 17994679]
CHO-K1	IC₅₀	67.3 3 Compound: NA	Agonist activity at GPR109A receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced intracellular cAMP production by Flashplate assay Agonist activity at GPR109A receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced intracellular cAMP production by Flashplate assay	[PMID: 17452318]
CHO-K1	EC₅₀	1.4 3 Compound: nicotinic acid	Agonist activity at human GPR109A receptor expressed in CHO-K1 cells by [35S]GTPgammaS guanine nucleotide exchange assay Agonist activity at human GPR109A receptor expressed in CHO-K1 cells by [35S]GTPgammaS guanine nucleotide exchange assay	[PMID: 18760600]
COS-7	EC₅₀	0.78 3 Compound: 3	Agonist activity at human recombinant GPR109a transfected in african green monkey COS-7 cells after 20 mins by [35S]GTPgammaS binding assay Agonist activity at human recombinant GPR109a transfected in african green monkey COS-7 cells after 20 mins by [35S]GTPgammaS binding assay	[PMID: 24900524]
CHO	IC₅₀	0.14 3 Compound: Niacin	Displacement of [3H]niacin from human GPR109A expressed in CHO cells Displacement of [3H]niacin from human GPR109A expressed in CHO cells	[PMID: 19309152]
CHO-K1	IC₅₀	67.3 3 Compound: NA	Agonist activity at GPR109A receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced intracellular cAMP production by Flashplate assay Agonist activity at GPR109A receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced intracellular cAMP production by Flashplate assay	[PMID: 17452318]
HEK293	IC₅₀	> 500 3 Compound: niacin	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
CHO	IC₅₀	0.14 3 Compound: niacin	Displacement of [3H]Niacin from human niacin receptor expressed in CHO cells Displacement of [3H]Niacin from human niacin receptor expressed in CHO cells	[PMID: 18477506]
CHO-K1	IC₅₀	0.13 3 Compound: nicotinic acid	Displacement of [3H]nicotinic acid from human GPR109A receptor expressed in CHO-K1 cells Displacement of [3H]nicotinic acid from human GPR109A receptor expressed in CHO-K1 cells	[PMID: 18760600]
HEK-293T	IC₅₀	249 1 Compound: Nicotinic acid	Displacement of [3H]-nicotinic acid from N-flag-tagged human HCA2 receptor expressed in HEK293T cell membranes by scintillation counting analysis Displacement of [3H]-nicotinic acid from N-flag-tagged human HCA2 receptor expressed in HEK293T cell membranes by scintillation counting analysis	[PMID: 25737085]
CHO	IC₅₀	0.15 3 Compound: nicotinic acid	Displacement of [3H]nicotinic acid from human GPR109A receptor expressed in CHO cells Displacement of [3H]nicotinic acid from human GPR109A receptor expressed in CHO cells	[PMID: 18752940]
COS-7	EC₅₀	0.78 3 Compound: 3	Agonist activity at human recombinant GPR109a transfected in african green monkey COS-7 cells after 20 mins by [35S]GTPgammaS binding assay Agonist activity at human recombinant GPR109a transfected in african green monkey COS-7 cells after 20 mins by [35S]GTPgammaS binding assay	[PMID: 24900524]
HEK-293T	EC₅₀	5 3 Compound: Niacin	Agonist activity at GPR109A receptor (unknown origin) expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS binding based microbeta scintillation counting analysis Agonist activity at GPR109A receptor (unknown origin) expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS binding based microbeta scintillation counting analysis	[PMID: 32199732]
CHO	IC₅₀	1 3 Compound: niacin	Agonist activity at human niacin receptor expressed in CHO cells by GTPgammaS binding assay Agonist activity at human niacin receptor expressed in CHO cells by GTPgammaS binding assay	[PMID: 18477506]
HEK293	IC₅₀	>500 3 Compound: niacin	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HL-60	CC₅₀	> 200 3 Compound: Niacin	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 28238612]
HEK-293T	EC₅₀	5 3 Compound: Niacin	Agonist activity at GPR109A receptor (unknown origin) expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS binding based microbeta scintillation counting analysis Agonist activity at GPR109A receptor (unknown origin) expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS binding based microbeta scintillation counting analysis	[PMID: 32199732]
HSC-2	CC₅₀	> 200 3 Compound: Niacin	Cytotoxicity against human HSC2 cells after 48 hrs by MTT assay Cytotoxicity against human HSC2 cells after 48 hrs by MTT assay	[PMID: 28238612]
HSC-3	CC₅₀	> 200 3 Compound: Niacin	Cytotoxicity against human HSC3 cells after 48 hrs by MTT assay Cytotoxicity against human HSC3 cells after 48 hrs by MTT assay	[PMID: 28238612]
HL-60	CC₅₀	>200 3 Compound: Niacin	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 28238612]
HSC-2	CC₅₀	>200 3 Compound: Niacin	Cytotoxicity against human HSC2 cells after 48 hrs by MTT assay Cytotoxicity against human HSC2 cells after 48 hrs by MTT assay	[PMID: 28238612]
HSC-4	CC₅₀	> 200 3 Compound: Niacin	Cytotoxicity against human HSC4 cells after 48 hrs by MTT assay Cytotoxicity against human HSC4 cells after 48 hrs by MTT assay	[PMID: 28238612]
HSC-3	CC₅₀	>200 3 Compound: Niacin	Cytotoxicity against human HSC3 cells after 48 hrs by MTT assay Cytotoxicity against human HSC3 cells after 48 hrs by MTT assay	[PMID: 28238612]
L1210	IC₅₀	> 500 3 Compound: Niacin	Cytotoxicity against mouse L1210 cells assessed as growth inhibition after 48 hrs by coulter counter method Cytotoxicity against mouse L1210 cells assessed as growth inhibition after 48 hrs by coulter counter method	[PMID: 28238612]
CHO-K1	EC₅₀	1 3 Compound: Niacin	Agonist activity at human GPR109A expressed in CHOK1 cells by [35S]GTPgammaS binding assay Agonist activity at human GPR109A expressed in CHOK1 cells by [35S]GTPgammaS binding assay	[PMID: 19309152]
HSC-4	CC₅₀	>200 3 Compound: Niacin	Cytotoxicity against human HSC4 cells after 48 hrs by MTT assay Cytotoxicity against human HSC4 cells after 48 hrs by MTT assay	[PMID: 28238612]
CHO-K1	EC₅₀	1 3 Compound: niacin	Agonist activity at human GPR109A expressed in CHOK1 cells by [35S]GTP-gamma-S binding assay Agonist activity at human GPR109A expressed in CHOK1 cells by [35S]GTP-gamma-S binding assay	[PMID: 17994679]
L1210	IC₅₀	>500 3 Compound: Niacin	Cytotoxicity against mouse L1210 cells assessed as growth inhibition after 48 hrs by coulter counter method Cytotoxicity against mouse L1210 cells assessed as growth inhibition after 48 hrs by coulter counter method	[PMID: 28238612]
CHO-K1	EC₅₀	1.4 3 Compound: nicotinic acid	Agonist activity at human GPR109A receptor expressed in CHO-K1 cells by [35S]GTPgammaS guanine nucleotide exchange assay Agonist activity at human GPR109A receptor expressed in CHO-K1 cells by [35S]GTPgammaS guanine nucleotide exchange assay	[PMID: 18760600]
CHO-K1	EC₅₀	47 1 Compound: Nicotinic acid	Agonist activity at HCA2 receptor (unknown origin) expressed in CHOK1 cells assessed as ERK1/2 phosphorylation by ELISA Agonist activity at HCA2 receptor (unknown origin) expressed in CHOK1 cells assessed as ERK1/2 phosphorylation by ELISA	[PMID: 25737085]
CHO-K1	EC₅₀	47 1 Compound: Nicotinic acid	Agonist activity at HCA2 receptor (unknown origin) expressed in CHOK1 cells assessed as ERK1/2 phosphorylation by ELISA Agonist activity at HCA2 receptor (unknown origin) expressed in CHOK1 cells assessed as ERK1/2 phosphorylation by ELISA	[PMID: 25737085]
CHO	EC₅₀	51 1 Compound: niacin, Niaspan	Agonist activity at human GPR109a expressed in CHO cells assessed as decrease in forskolin-stimulated cAMP production by HTRF assay Agonist activity at human GPR109a expressed in CHO cells assessed as decrease in forskolin-stimulated cAMP production by HTRF assay	[PMID: 22435740]
CHO-K1	EC₅₀	527 1 Compound: NA	Agonist activity at cloned human GPR109A receptor expressed in CHO-K1 cells by [35S]GTPgammaS binding assay Agonist activity at cloned human GPR109A receptor expressed in CHO-K1 cells by [35S]GTPgammaS binding assay	[PMID: 20184326]
CHO	EC₅₀	99 1 Compound: NA, niacin	Agonist activity at human recombinant GPR109a expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation Agonist activity at human recombinant GPR109a expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation	[PMID: 24900372]
CHO-K1	EC₅₀	580 1 Compound: NA	Activation of GPR109A receptor in CHOK1 cells assessed as ERK1/2 MAP kinase activation by ELISA Activation of GPR109A receptor in CHOK1 cells assessed as ERK1/2 MAP kinase activation by ELISA	[PMID: 17452318]
CHO	EC₅₀	100 1 Compound: Nicotinic acid	Agonist activity at human recombinant GPR109a expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation Agonist activity at human recombinant GPR109a expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation	[PMID: 24900295]
CHO-K1	IC₅₀	0.13 3 Compound: nicotinic acid	Displacement of [3H]nicotinic acid from human GPR109A receptor expressed in CHO-K1 cells Displacement of [3H]nicotinic acid from human GPR109A receptor expressed in CHO-K1 cells	[PMID: 18760600]
HEK-293T	IC₅₀	249 1 Compound: Nicotinic acid	Displacement of [3H]-nicotinic acid from N-flag-tagged human HCA2 receptor expressed in HEK293T cell membranes by scintillation counting analysis Displacement of [3H]-nicotinic acid from N-flag-tagged human HCA2 receptor expressed in HEK293T cell membranes by scintillation counting analysis	[PMID: 25737085]
CHO-K1	IC₅₀	67.3 3 Compound: NA	Agonist activity at GPR109A receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced intracellular cAMP production by Flashplate assay Agonist activity at GPR109A receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced intracellular cAMP production by Flashplate assay	[PMID: 17452318]
CHO-K1	EC₅₀	527 1 Compound: NA	Agonist activity at cloned human GPR109A receptor expressed in CHO-K1 cells by [35S]GTPgammaS binding assay Agonist activity at cloned human GPR109A receptor expressed in CHO-K1 cells by [35S]GTPgammaS binding assay	[PMID: 20184326]
CHO-K1	EC₅₀	580 1 Compound: NA	Activation of GPR109A receptor in CHOK1 cells assessed as ERK1/2 MAP kinase activation by ELISA Activation of GPR109A receptor in CHOK1 cells assessed as ERK1/2 MAP kinase activation by ELISA	[PMID: 17452318]
COS-7	EC₅₀	0.78 3 Compound: 3	Agonist activity at human recombinant GPR109a transfected in african green monkey COS-7 cells after 20 mins by [35S]GTPgammaS binding assay Agonist activity at human recombinant GPR109a transfected in african green monkey COS-7 cells after 20 mins by [35S]GTPgammaS binding assay	[PMID: 24900524]
HEK-293T	EC₅₀	5 3 Compound: Niacin	Agonist activity at GPR109A receptor (unknown origin) expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS binding based microbeta scintillation counting analysis Agonist activity at GPR109A receptor (unknown origin) expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS binding based microbeta scintillation counting analysis	[PMID: 32199732]
HEK-293T	IC₅₀	249 1 Compound: Nicotinic acid	Displacement of [3H]-nicotinic acid from N-flag-tagged human HCA2 receptor expressed in HEK293T cell membranes by scintillation counting analysis Displacement of [3H]-nicotinic acid from N-flag-tagged human HCA2 receptor expressed in HEK293T cell membranes by scintillation counting analysis	[PMID: 25737085]
HEK293	IC₅₀	> 500 3 Compound: niacin	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HL-60	CC₅₀	> 200 3 Compound: Niacin	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 28238612]
HSC-2	CC₅₀	> 200 3 Compound: Niacin	Cytotoxicity against human HSC2 cells after 48 hrs by MTT assay Cytotoxicity against human HSC2 cells after 48 hrs by MTT assay	[PMID: 28238612]
HSC-3	CC₅₀	> 200 3 Compound: Niacin	Cytotoxicity against human HSC3 cells after 48 hrs by MTT assay Cytotoxicity against human HSC3 cells after 48 hrs by MTT assay	[PMID: 28238612]
HSC-4	CC₅₀	> 200 3 Compound: Niacin	Cytotoxicity against human HSC4 cells after 48 hrs by MTT assay Cytotoxicity against human HSC4 cells after 48 hrs by MTT assay	[PMID: 28238612]
L1210	IC₅₀	> 500 3 Compound: Niacin	Cytotoxicity against mouse L1210 cells assessed as growth inhibition after 48 hrs by coulter counter method Cytotoxicity against mouse L1210 cells assessed as growth inhibition after 48 hrs by coulter counter method	[PMID: 28238612]

体外実験

Niacin (0-900 μM, 42 hours) significantly increases GSH levels and decreases ROS levels, and affects the expression of genes related to apoptosis and lipid metabolism^[1].
Niacin (0-40 μM, 24 hours) can inhibit cancer invasive activity at low dose but with no influence on proliferation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[1]

Cell Line:	Cumulus cells and oocytes of prepubertal gilts
Concentration:	600 μM
Incubation Time:	42 hours
Result:	Up-regulated the relative expression of the anti-apoptotic gene BCL2 and lipid metabolism gene ACACA while down-regulated the pro-apoptotic gene BAX.

Cell Proliferation Assay^[2]

Cell Line:	Rat ascites hepatoma cell line of AH109A
Concentration:	0-40 μM
Incubation Time:	24 hours
Result:	Had no effect on the proliferation of AH109A cells but suppressed cell invasion from 2.5 μM to 40 μM.

体内実験

Niacin (subcutaneous injection, 3-300 mg/kg, once) can induce vasodilation in a dose-dependent manner within minutes in male C57BL/6 mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6 mice^[3]
Dosage:	3-300 mg/kg
Administration:	Subcutaneous injection; once
Result:	Induced vasodilation in a dose-dependent manner.

分子量

123.11

分子式

C₆H₅NO₂

CAS 番号

59-67-6

Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=CC=CN=C1)O

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Microorganisms

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Store at room temperature 3 years

*In solvent : -80°C, 6 months; -20°C, 1 month (Store at room temperature 3 years)

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (406.14 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 10 mg/mL (81.23 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	8.1228 mL	40.6141 mL	81.2282 mL
5 mM	1.6246 mL	8.1228 mL	16.2456 mL
10 mM	0.8123 mL	4.0614 mL	8.1228 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (16.90 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (16.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (16.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 12.5 mg/mL (101.54 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.96%

Select Batch:

データシート (279 KB) SDS (393 KB)

COA (248 KB) HNMR (111 KB) RP-HPLC (228 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Areeg M Almubarak, et al. Supplementation with Niacin during in vitro maturation improves the quality of porcine embryos. Theriogenology. 2021 Jul 15;169:36-46. doi: 10.1016/j.theriogenology.2021.04.005. Epub 2021 Apr 18. [Content Brief]

[2]. Nobuhiro Hirakawa, et al. Anti-invasive activity of niacin and trigonelline against cancer cells. Biosci Biotechnol Biochem. 2005 Mar;69(3):653-8. [Content Brief]

[3]. Kang Cheng, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6682-7. [Content Brief]

[4]. Bruckert E, et al. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010 Jun;210(2):353-61. [Content Brief]

[5]. Wan P, et al. Pellagra: a review with emphasis on photosensitivity. Br J Dermatol. 2011 Jun;164(6):1188-200. [Content Brief]

[6]. Ishii N, et al. Pellagra among chronic alcoholics: clinical and pathological study of 20 necropsy cases. J Neurol Neurosurg Psychiatry. 1981 Mar;44(3):209-15. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	8.1228 mL	40.6141 mL	81.2282 mL	203.0704 mL
	5 mM	1.6246 mL	8.1228 mL	16.2456 mL	40.6141 mL
	10 mM	0.8123 mL	4.0614 mL	8.1228 mL	20.3070 mL
	15 mM	0.5415 mL	2.7076 mL	5.4152 mL	13.5380 mL
	20 mM	0.4061 mL	2.0307 mL	4.0614 mL	10.1535 mL
	25 mM	0.3249 mL	1.6246 mL	3.2491 mL	8.1228 mL
	30 mM	0.2708 mL	1.3538 mL	2.7076 mL	6.7690 mL
	40 mM	0.2031 mL	1.0154 mL	2.0307 mL	5.0768 mL
	50 mM	0.1625 mL	0.8123 mL	1.6246 mL	4.0614 mL
	60 mM	0.1354 mL	0.6769 mL	1.3538 mL	3.3845 mL
	80 mM	0.1015 mL	0.5077 mL	1.0154 mL	2.5384 mL
DMSO	100 mM	0.0812 mL	0.4061 mL	0.8123 mL	2.0307 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Niacin Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Niacin59-67-6Nicotinic acid Vitamin B3Vitamin B3Vitamin B 3Vitamin B-3MOFsEnvironmental PollutantsEndogenous MetaboliteMetal-Organic FrameworksEnvironmental Contaminantsapoptosiscardiovascular diseasescancerInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

Niacin (Synonyms: Nicotinic acid; Vitamin B3; ニコチン酸)

カスタマーレビュー

Other Forms of Niacin:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Niacin Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Niacin (Synonyms: Nicotinic acid; Vitamin B3; ニコチン酸)

カスタマーレビュー

Other Forms of Niacin:

Niacin 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Niacin 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Niacin Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report